Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Studie för att utvärdera LB-LR1109 för behandling av solida tumörer (LB-LR1109)

15 november 2026 uppdaterad av: LG Chem

En fas 1, först i människa, öppen etikett, multicenter, dosökningsstudie för att utvärdera säkerheten, tolerabiliteten, farmakokinetiken och farmakodynamiken hos LB-LR1109 för behandling av avancerade eller metastaserande solida tumörer

This is a Phase 1a/1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)/Recommended Phase 2 dose (RP2D) and to evaluate safety, tolerability, preliminary efficacy, pharmacokinetics, immunogenicity, pharmacodynamics of LB-LR1109 as monotherapy in participants with advanced and/or metastatic non small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma (RCC), urothelial carcinoma, or malignant melanoma and no available standard of care treatment options, and as combination therapy with atezolizumab in participants with advanced and/or metastatic NSCLC.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

76

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Key Inclusion Criteria:

  1. Age ≥18 years old at the time of signing the ICF.

  2. (Phase 1a only) Participants must have 1 of the following histologically confirmed advanced or metastatic solid tumors with measurable or non-measurable disease as determined by RECIST v1.1,

    - NSCLC, HNSCC, RCC, urothelial carcinoma, or malignant melanoma.

  3. (Phase 1a only) Participants who have metastatic disease which has progressed during or after approved standard therapies or are intolerant to approved therapies, or for which the participant refuses or is ineligible for standard therapy.

  4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.

  5. Life expectancy ≥12 weeks.

  6. Participants with adequate organ function

  7. No potential for childbearing or agree to use adequate contraception

  8. Ability to understand the study purpose and procedures and have the willingness to sign a written informed consent document.

  9. (Phase 1b only ) Must have histologically confirmed advanced or metastatic NSCLC without actionable genomic alteration that have approved therapies in the location where the participant's live and with measurable disease as determined by RECIST v1.1

Key Exclusion Criteria:

  1. Clinically significant cardiac disease or cardiac failure.
  2. Untreated or unstable brain or central nervous system (CNS) metastases or Leptomeningeal disease
  3. Participants with any concurrent active malignancies
  4. Has received prior therapy targeting LILRB or immunoglobulin-like transcript pathway.
  5. History of life-threatening toxicity related to prior immune therapy
  6. Has not recovered to ≤ Grade 1 or baseline from AEs and/or complications from prior surgical intervention or any anti-cancer treatment before starting study treatment
  7. Participants must not have an active, known, or suspected autoimmune disease.
  8. Evidence of active infection requiring IV antibiotic treatment ≤7 days prior to initiation of study treatment therapy (does not apply to viral infections that are presumed to be associated with the underlying tumor type required for study entry).
  9. Pregnant or lactating or expecting to conceive a child during the study or within 6 months after the last dose of study intervention.
  10. Any condition that would, in the Investigator's judgment, interfere with full participation in the study, including administration of study intervention and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
  11. (Phase 1b only) Participants who were previously exposed to atezolizumab

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Icke-randomiserad
  • Interventionsmodell: Sekventiell tilldelning
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: fas 1a: Dosupptrapping / LB-LR1109 monoterapi

intravenous administration

Experimentell: Fas 1b: Dosupptrappning / LB-LR1109 i kombination med Atezolizumab

intravenous administration

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Phase 1a: MTD and/or RP2D of LB-LR1109 as monotherapy in participants with advanced or metastatic solid tumors / Phase 1b: MTD and/or RP2D of LB-LR1109 as combination therapy with atezolizumab in participants with advanced or metastatic NSCLC
Tidsram: through study completion, an average of 1year

Number of participants with dose-limiting toxicities (DLTs)

through study completion, an average of 1year
Phase 1a: Incidence of Treatment-Emergent Adverse Events of LB-LR1109 as monotherapy / Phase 1b: Incidence of Treatment-Emergent Adverse Events of LB-LR1109 as combination therapy with atezolizumab
Tidsram: through study completion, an average of 1year

Incidence, severity (assessed by NCI CTCAE v5.0), and causality of AEs

through study completion, an average of 1year

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Phase 1a / 1b: Preliminary efficacy of LB-LR1109 as monotherapy and as combination therapy with atezolizumab
Tidsram: through study completion, an average of 1year

ORR(overall response rate) assessed by RECIST v1.1 (%)

through study completion, an average of 1year
Phase 1a / 1b: Antitumor efficacy of LB-LR1109 as monotherapy and as combination therapy with atezolizumab
Tidsram: through study completion, an average of 1year

PFS(Progression free survival)

through study completion, an average of 1year
Phase 1a/1b: Antitumor efficacy of LB-LR1109 as monotherapy and as combination therapy with atezolizumab
Tidsram: through study completion, an average of 1year

OS (Overall survival) (months)

through study completion, an average of 1year
Phase 1a / 1b: Pharmacokinetic profile of LB-LR1109 as monotherapy and as combination therapy with atezolizumab
Tidsram: through study completion, an average of 1year

Cmax (Maximum serum drug concentration)

through study completion, an average of 1year
Phase 1a / 1b: Characterize PK of LB-LR1109 as monotherapy and as combination therapy with atezolizumab
Tidsram: through study completion, an average of 1year

Area under the concentration-time curve (AUC) 0-last

through study completion, an average of 1year
Phase 1a / 1b: Immunogenicity of LB-LR1109 as monotherapy and as combination therapy with atezolizumab
Tidsram: through study completion, an average of 1year

Number and percentage of participants with ADAs

through study completion, an average of 1year

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

5 juni 2024

Primärt slutförande (Beräknad)

1 november 2027

Avslutad studie (Beräknad)

1 december 2028

Studieregistreringsdatum

Först inskickad

16 februari 2024

Först inskickad som uppfyllde QC-kriterierna

22 mars 2024

Första postat (Faktisk)

27 mars 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

17 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

15 november 2026

Senast verifierad

1 november 2026

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera